Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

New study results released – the European Association for the Study of Diabetes (EASD)

The logo of the European Association for the Study of Diabetes and a neuropad screening test.

A new study presented at the specialist Diabetic Foot Study Group (DFSG) of the European Association for the Study of Diabetes (EASD) in Stuttgart, Germany, in September 2016 provides further evidence of the high sensitivity that neuropad® has for the prediction of future foot ulceration in people with diabetes.

The prospective study conducted by lead investigator Dr Irene Sanz Corbalán and colleagues enrolled 263 patients consecutively from the Diabetic Foot Unit of the Complutense University of Madrid between July 2011 and April 2015. Diabetic patients without an active foot ulcer were classified by the International Working Group of Diabetic Foot (IWGDF) risk stratification system. Diabetic neuropathy was evaluated according to the results of the Semmes-Weinstein Monofilament (SWM) or Biothesiometer and using the neuropad® sudomotor function test (SFT).

Results showed that 60 (22.8%) patients developed a diabetic foot ulcer (DFU) during a mean follow-up of 41.55 ± 3.5 [35-48] months. 10 (16.7%) patients who were not diagnosed as having diabetic neuropathy by the SWM/Biothesiometer and were classified into the group risk 0 (without risk for developing a foot ulcer) went on to develop a foot ulcer during follow-up. In contrast, all patients who tested positive for sudomotor dysfunction, and despite some having a 0 risk using conventional sensory tests, went on to develop DFU during the follow-up period.

SFT was considered an independent and statistically significant factor in the final Cox regression model of DFU prediction during the follow up [p=0.002; HR: 4.3 (CI: 1.7-11.1)].

The diagnostic prediction model regarding the development of diabetic foot ulcer in follow-up showed that SWM/Biothesiometer had 83.33% sensitivity and 50.74% of specificity whilst neuropad® demonstrated 100% of sensitivity and 31.53% of specificity for future foot ulceration.

The investigators concluded that Neuropad identifies earlier and with greater accuracy patients with diabetes that are at risk of developing DFU compared with the standard neurological sensory tests. The results of this research add to the evidence base that sudomotor function should be included as a risk factor in the classification system for diabetic foot disease because the standard sensory tests under-diagnose the overall risk for ulceration. The study is now in publication.

Find out more about the DFSG (opens in new tab).